Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections

Current antiviral therapies, such as pegylated interferon-α and nucleos(t)ide analogues, effectively improve the quality of life of patients with chronic hepatitis B. However, they can only control the infection rather than curing infected hepatocytes. Complete HBV cure is hampered by the lack of th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology Jg. 75; H. 3; S. 706 - 717
Hauptverfasser:	Martinez, Maria Guadalupe, Boyd, Anders, Combe, Emmanuel, Testoni, Barbara, Zoulim, Fabien
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Netherlands Elsevier B.V 01.09.2021 Elsevier Science Ltd Elsevier
Schlagworte:	Antiviral agents Antiviral Agents - pharmacology Antiviral Agents - therapeutic use cccDNA chronic hepatitis B Chronic infection Circular DNA Clinical trials direct-acting antivirals DNA, Circular - pharmacology DNA, Circular - therapeutic use HBV cure Hepatitis B Hepatitis B - drug therapy Hepatitis B surface antigen Hepatitis B virus - genetics Hepatocytes Human health and pathology Humans Hépatology and Gastroenterology Interferon Life Sciences Metal-Organic Frameworks - pharmacology Metal-Organic Frameworks - therapeutic use Quality of life Therapeutic targets α-Interferon chronic hepatitis B HBV cure cccDNA direct-acting antivirals
ISSN:	0168-8278, 1600-0641, 1600-0641
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!